Richard J Ulevitch

This inventor holds 21 USPTO granted patents, plus 2 CIPO patents and 1 EPO patent. Top assignees: Scripps Research Institute, Scripps Clinic and Research Foundation, Other. Active years: 1989-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard J Ulevitch. Retrieved from https://idiyas.com/inventor/richard-j-ulevitch

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21

% Patents Active = 81.0

CIPO Patents = 2

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 3.3

ph-index = 7

Forward Citations = 113(Granted Patents)

Location History:

Del Mar, CA (US) (1989 - 2008)
La Jolla, CA (US) (2017)

Company Filing History:

18 out of 1,206

Scripps Research Institute

patents

1 out of 122

Scripps Clinic and Research Foundation

patents

2 out of 834,453

Other

patents

Years Active: 1989-2017

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9765061 - Trail enhancers for the selective killing of cancer cells (2017-09-19),

2. 9604950 - Trail enhancers for the selective killing of cancer cells (2017-03-28),

3. 7326569 - Hybrid cells producing monoclonal anti-CD14 antibodies (2008-02-05),

4. 6884417 - Monoclonal antibodies immunoreactive with lipopolysaccharide binding protein (LBP) and methods of their use (2005-04-26),

5. 6495332 - Methods and compositions for ameliorating the symptoms of sepsis (2002-12-17),

6. 6444206 - Methods and compositions for inhibiting CD14 mediated cell activation (2002-09-03),

7. 6297049 - Methods and compositions for ameliorating the symptoms of sepsis (2001-10-02),

8. 6232080 - Monoclonal antibodies immunoreactive with lipopolysaccharide binding protein (LBP) and methods of their use (2001-05-15),

9. 6168790 - Use of antibodies to block the effects of gram-positive bacteria and mycobacteria (2001-01-02),

10. 6045795 - Methods and compositions for ameliorating the symptoms of sepsis (2000-04-04),

11. 6010856 - Assay systems and methods for measuring P38 map kinase, and modulators (2000-01-04),

12. 5871937 - Acute phase protein modulating endotoxic activity of (1999-02-16),

13. 5837810 - Polypeptides of lipopolysaccharide binding protein (1998-11-17),

14. 5820858 - Methods and compositions for inhibiting CD14 mediated cell activation (1998-10-13),

15. 5753504 - Monoclonal antibodies immunoreactive with lipopolysaccharide binding (1998-05-19),

Title: Richard J Ulevitch: A Pioneer in Cancer Research and Innovative Patents

Introduction

Richard J Ulevitch is a prominent figure in the field of cancer research, residing in Del Mar, California. With an impressive portfolio of 21 patents, he has made significant contributions to medical science, particularly in the area of cancer therapies.

Latest Patents

One of Ulevitch's notable innovations is the patent for "Trail enhancers for the selective killing of cancer cells." This invention focuses on methods for inducing apoptosis, arresting the cell cycle, and inhibiting cellular proliferation in tumor cells. It involves the administration of an effective amount of an N-acyl homoserine lactone analog (AHL) to the patient, potentially in conjunction with tumor modulating agents like tumor necrosis factor (TNF) related apoptosis-inducing ligand (TRAIL). Additionally, the patent provides novel bioactive analogs of N-acyl homoserine lactone, expanding the possibilities for targeted cancer treatment.

Career Highlights

Ulevitch has held significant positions at esteemed institutions, including the Scripps Research Institute. His work there has been instrumental in advancing the understanding of cellular mechanisms in cancer and has led to groundbreaking therapeutic approaches.

Collaborations

Throughout his career, Richard J Ulevitch has collaborated with numerous respected professionals in the field, including Peter S Tobias and John C Mathison. These collaborations have facilitated the exchange of ideas and have driven forward the research into novel cancer treatments.

Conclusion

In conclusion, Richard J Ulevitch's innovative work and prolific patent portfolio underscore his commitment to advancing cancer research. His inventions, particularly in the realm of selective cell death in tumors, promise to have a lasting impact on therapeutic strategies for cancer treatment. Ulevitch continues to inspire future generations of scientists and inventors in the quest for effective cancer therapies.

Profile summary based on public USPTO records.